BenevolentAI, a leader in AI-driven drug discovery, has unveiled its 2023 Annual Report, outlining significant achievements and financial performance, and has announced the date for its 2024 Annual General Meeting in Luxembourg.
BenevolentAI Announces 2023 Annual Report and Date for 2024 Annual General Meeting
LONDON, March 20, 2024 – In a significant development in the biopharmaceutical industry, BenevolentAI, a pioneering firm at the interface of artificial intelligence (AI) and biopharma drug discovery, has announced the release of its 2023 Annual Report. This comprehensive document outlines the company’s achievements and financial health over the past year. In addition, the company has set the stage for its 2024 Annual General Meeting (AGM), scheduled for May 2, 2024, at a prestigious location in Luxembourg, further affirming its commitment to transparency and shareholder engagement.
BenevolentAI stands out in the field of drug discovery for its innovative use of AI to accelerate the development of novel treatments for complex diseases. The company’s proprietary Benevolent Platform™ harnesses cutting-edge AI technologies, combined with in-house scientific expertise and state-of-the-art wet-lab facilities, to uncover new biology, predict novel targets, and develop first-in-class or best-in-class drugs.
The significance of BenevolentAI’s work cannot be overstated, especially in an era where traditional drug discovery methods face challenges of high costs, long timelines, and increasing complexity of diseases. By integrating AI into the early stages of drug development, the company aims to streamline the process, reducing both the time and investment required to bring new therapies to market.
The 2023 Annual Report and the convening notice for the 2024 AGM are available to shareholders and the general public on the company’s website, providing detailed insights into the company’s operational and financial performance. Interested parties are encouraged to review these documents to understand better the strides BenevolentAI is making in redefining drug discovery.
Headquartered in London, with additional facilities in Cambridge (UK) and an office in New York, BenevolentAI’s multinational presence underscores its ambition to be at the forefront of leveraging AI for medical breakthroughs. The company maintains a diverse business model, including discovery collaborations with leading pharmaceutical firms like AstraZeneca and Merck, which emphasizes its pivotal role in the global healthcare ecosystem.
The announcement of the 2023 Annual Report and the forthcoming AGM underscores BenevolentAI’s commitment to maintaining an open dialogue with its shareholders and the wider community. Shareholders on record as of April 18, 2024, are eligible to participate and vote at the AGM, where they can engage directly with the company’s leadership on key decisions and strategic directions.
As the date for the 2024 AGM approaches, BenevolentAI continues to emphasize its mission to serve patients through AI-driven innovation. The company’s achievements, underscored in its annual report, highlight its ongoing efforts to tackle some of healthcare’s most formidable challenges, offering hope for faster, more effective development of life-saving treatments.
